Integrated Systems Biology Identifies Disruptions in Mitochondrial Function and Metabolism as Key Contributors to HFpEF
Heart failure with preserved ejection fraction (HFpEF) accounts for ∼50% of HF cases. The ZSF1-obese rat model recapitulates clinical features of HFpEF including hypertension, obesity, metabolic syndrome, exercise intolerance, and diastolic dysfunction. We utilized a systems-biology approach to define the metabolic and transcriptional signatures to gain mechanistic insight into pathways contributing to HFpEF development. Male ZSF1-obese, ZSF1-lean hypertensive controls, and WKY (wild-type) controls were compared at 14 weeks of age for extensive physiological phenotyping and left ventricle (LV) tissue harvesting for unbiased-metabolomics, RNA-sequencing, and mitochondrial morphology and function. Utilizing ZSF1-lean and WKY controls enabled a distinction between hypertension-driven molecular changes driving HFpEF pathology, versus hypertension + metabolic syndrome. Comparison of ZSF1-lean vs WKY (ie, hypertension-exclusive effects) revealed metabolic remodeling suggesting increased aerobic glycolysis, decreased β-oxidation, and dysregulated purine and pyrimidine metabolism with few transcriptional changes. ZSF1-obese rats displayed worsened metabolic remodeling and robust transcriptional remodeling highlighted by upregulation of inflammatory genes and downregulation of the mitochondrial structure/function and metabolic processes. Integrated network analysis of metabolomic and RNAseq datasets revealed downregulation of most catabolic energy producing pathways, manifesting in a marked decrease in the energetic state (ie, reduced ATP/ADP, PCr/ATP). Cardiomyocyte ultrastructure analysis revealed decreased mitochondrial area, size, and cristae density, as well as increased lipid droplet content in HFpEF hearts. Impaired mitochondrial function was demonstrated by decreased substrate-mediated respiration and dysregulated calcium handling. Collectively, the integrated omics approach applied here provides a framework to uncover novel genes, metabolites, and pathways underlying HFpEF, with an emphasis on mitochondrial energy metabolism as a potential interventional target.
Authors
- Andrew Gibb (ORCID: https://orcid.org/0000-0003-2770-430X)
- Carmen Choya-Foces (ORCID: https://orcid.org/0000-0001-5804-1700)
- John W. Elrod (ORCID: https://orcid.org/0000-0003-3925-2224)
- Kyle B. LaPenna (ORCID: https://orcid.org/0000-0003-0470-0138)
- David J. Lefer (ORCID: https://orcid.org/0000-0003-2293-7278)
- Jake E. Doiron (ORCID: https://orcid.org/0000-0002-4584-4819)
- Ryan B. Gaspar (ORCID: https://orcid.org/0000-0002-7922-3893)
- Traci T. Goodchild (ORCID: https://orcid.org/0009-0009-7377-780X)
- Michelle Conwell
- Thomas E. Sharp (ORCID: https://orcid.org/0000-0001-8706-9825)
- Michael P. Lazaropoulos (ORCID: https://orcid.org/0000-0002-3872-3744)
- Nadina Latchman (ORCID: https://orcid.org/0000-0003-4161-3770)
- Zhen Li (ORCID: https://orcid.org/0000-0002-2250-7035)
- Huijing Xia (ORCID: https://orcid.org/0000-0001-7024-5693)
- Yin Fei Tan
Institutions
- Cedars-Sinai Medical Center (US)
- Fox Chase Cancer Center (US)
- University of South Florida (US)
- Cedars-Sinai Smidt Heart Institute (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- Temple University (US)
Publication Details
- Journal
- JACC Basic to Translational Science
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.jacbts.2025.101334
- Citations
- 5
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 6.94
Funders
- American Heart Association
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke